An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
1 LRiG, Department of Health Data Science, University of Liverpool, Liverpool, UK
2 Coldingham Analytical Services, Berwickshire, UK
3 Hare Research, North Yorkshire, UK
* Corresponding author Email: rebecca.bresnahan@liverpool.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
Response by Dr Angela Boland on 12 August 2024 at 3:30 PM
Authors response to comment
Based on the available evidence, the authors found that the benefits of the imaging technologies considered as part of the appraisal were limited. In some scenarios, use of these imaging technologies led to some patients being falsely identified as having no liver disease, which would have had negative consequences for these patients. In all scenarios considered by the authors, costs were higher if imagining was introduced before biopsy.
Whilst biopsy is not without risks, the economic model attempts to balance these risks against the risks of falsely identifying patients as having no liver disease.
The costs of biopsy in the study are based on NHS Reference Costs; these take into account the time and materials used in the procedure.
The authors found it unlikely that the introduction of imaging prior to biopsy would be a cost effective use of NHS resources.
Response by Daniel on 20 October 2023 at 6:07 PM
The Future Of Health
This report appears to be recommending liver biopsy over non-invasive imaging. As a liver patient this is concerning to me and doesn’t seem to be safe or in patients’ best interest. Also I would be interested to see the cost analysis of the biopsy taking into count the hospital time involved.
An error has occurred in processing the XML document